Matthew Davids

Chief, Division of Lymphoma · Mass General Brigham

Credentials: · · ·

History

Hematology and Medical Oncology
Dana-Farber Cancer Institute
2008–2011
New York-Presbyterian Weill Cornell Medical Center and Memorial Sloan-Kettering Cancer Center
2005–2008
Harvard Medical School
Yale Univ Sch of Med
2001–2005
Harvard College
1997–2001

Development of Novel Therapeutic Strategies in Human Leukemias
National Cancer Institute · P01
Project lead · $391.7K · Dana-Farber Cancer Inst
1997–2030
Optimizing Novel Agent Combination Therapy for Previously Untreated, High Risk Chronic Lymphocytic Leukemia
National Cancer Institute · R01
Contact PI · $2M · Dana-Farber Cancer Inst
2022–2027
Comprehensive Dissection of the CLL Genome & Phenome to Improve Patient Outcomes
National Cancer Institute · P01
Project lead · $716.1K · Dana-Farber Cancer Inst
2016–2026

Acalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLL
Principal investigator · Active not recruiting · Phase 2
Dana-Farber Cancer Institute
2018–2027
Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RS
Principal investigator · Active not recruiting · Phase 1, Phase 2
Dana-Farber Cancer Institute
2018–2026
A Phase II Study of Venetoclax in Combination With Dose-adjusted EPOCH-R or R-CHOP for Patients With Richter's Syndrome
Principal investigator · Active not recruiting · Phase 2
Dana-Farber Cancer Institute
2017–2027
A Study of Ibrutinib + Obinutuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Principal investigator · Active not recruiting · Phase 1
Dana-Farber Cancer Institute
2015–2027